#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Familial amyotrophic lateral sclerosis Hormone-dependent prostate cancer Angiosarcoma metastatic Scleroderma associated digital ulcer Demyelination Adenocarcinoma pancreas Hypergammaglobulinaemia benign monoclonal Haemophagocytic lymphohistiocytosis Non-small cell lung cancer recurrent Metabolic disorder Neurofibroma Primary myelofibrosis Obesity Juvenile psoriatic arthritis Extra-osseous Ewing's sarcoma recurrent More trials…

    Learn about Rare Diseases

    Epidermolysis bullosa – Life with Disease Hereditary optic atrophy Fabry’s disease – Basic Information Glycogen storage disease type I – Life with Disease Crigler-Najjar syndrome – Trials in Disease Glomerulonephritis membranous – Basic Information Hereditary neuropathic amyloidosis – Trials in Disease Alveolar rhabdomyosarcoma – Basic Information Undifferentiated sarcoma – Basic Information Marfan’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cefalexin Monohydrate Emtricitabine Parsaclisib Hydrochloride Poltreg-T1D ANHYDROUS CALCIUM FOLINATE Nms-03305293 Ag13909 Pentixafor Gallium Ga-68 Bcmacp03 Napabucasin Gremubamab Asciminib Hydrochloride Other Immunosuppressants Relacorilant Tretinoin Tioguanine Iloprost Trometamol Ciclosporin A Riboflavin Sodium Phosphate Omp64 More therapies…

    Learn about Your Condition

    Choroid melanoma Retinoblastoma Oral neoplasm Periarthritis Infective uveitis Muscular dystrophy HIV infection Post-traumatic headache Tertiary adrenal insufficiency Myelodysplastic syndrome Placenta praevia Wheezing Malignant peritoneal neoplasm Testicular germ cell tumour Liver transplant More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic lymphocytic leukaemia

  • Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Nemtabrutinib
    • Acalabrutinib
    • Ibrutinib
    Belgium Czechia Denmark Germany Greece Norway +4

  • Long-Term Safety Study of BCMACP03, BCN-CP01, and 19CP02 for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, CLL, SLL, or Multiple Myeloma

    Recruiting

    3 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • 19Cp02
    • Bcmacp03
    Belgium Finland The Netherlands Spain

  • Study of venetoclax, obinutuzumab and zanubrutinib combination therapy in young patients with high-risk Chronic Lymphocytic Leukemia and residual disease

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Chlorphenamine Maleate
    • Lamivudine
    • Allopurinol
    Italy

  • Study on Zanubrutinib, Tislelizumab, and Sonrotoclax for Patients with Richter Transformation (a type of lymphoma)

    Recruiting

    2 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Tislelizumab
    • Zanubrutinib
    Austria Denmark Germany

  • Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Ibrutinib
    • Venetoclax
    Czechia France Hungary Italy Poland Spain

  • Study on Venetoclax and Epcoritamab for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Epcoritamab
    • Venetoclax
    Belgium Denmark Germany The Netherlands
Previous Page
1 … 3 4 5 6 7 … 13
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!